03.10.2007 12:00:00
|
Pfizer Hires New Vice President and Chief Talent Officer
Pfizer announced today that Dr. Tanya Clemons, a senior executive with
extensive experience in leadership and organization change at Microsoft
and IBM, will join Pfizer as vice president and Chief Talent Officer in
November.
Dr. Clemons will report to Mary McLeod, the senior vice president for
Worldwide Talent Development and Human Resources. She will be a member
of the Human Resources Leadership Team and Pfizer’s
Senior Management Team.
Dr. Clemons will have responsibility for enterprise-wide organization
development, talent and learning strategies and play a critical role in
shaping the new culture. In this role, she will lead the company’s
senior executive talent development, global people development and
succession processes with emphasis on identification, retention, and
development of executive level incumbent, replacement and high potential
individuals.
"At Pfizer, we have some of the best leaders
in the industry and we have very high expectations of them and of all of
our colleagues. We’re investing more in our
talent pipeline and making an ongoing commitment to developing our
people,” said Mary McLeod. "Tanya’s
depth of expertise and her practical experience designing and
implementing global processes and programs will be a real asset to our
business as we continue to implement our growth strategy.”
Dr. Clemons is currently the corporate vice president for People and
Organization Capability at Microsoft where she is responsible for
leadership development, talent management, employee learning and
training, organization development, and enterprise-wide change
initiatives. Prior to joining Microsoft, she held leadership roles at
IBM, Georgia-Pacific and Anheuser-Busch.
Dr. Clemons earned a B.A. in psychology from the University of New
Orleans and a Ph.D. in organizational psychology from Louisiana State
University.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.
Nachrichten zu Pfizer Inc.mehr Nachrichten
Analysen zu Pfizer Inc.mehr Analysen
19.12.24 | Pfizer Neutral | UBS AG | |
17.12.24 | Pfizer Buy | Jefferies & Company Inc. | |
17.12.24 | Pfizer Neutral | UBS AG | |
17.12.24 | Pfizer Neutral | JP Morgan Chase & Co. | |
12.12.24 | Pfizer Neutral | JP Morgan Chase & Co. |
Aktien in diesem Artikel
Pfizer Inc. | 26,11 | 0,38% |
Indizes in diesem Artikel
Dow Jones | 41 938,45 | -1,63% | |
S&P 500 | 5 827,04 | -1,54% | |
S&P 100 | 2 857,98 | -1,56% | |
NYSE US 100 | 16 447,86 | 0,76% |